FDA's New Vaccine and Biologics Chief: What You Need to Know

The U.S. Food and Drug Administration (FDA) recently appointed Dr. Katherine Szarama as the acting director of its Center for Biologics Evaluation and Research (CBER), the division responsible for overseeing vaccines, gene therapies, and the nation's blood supply. This leadership change follows the departure of Dr. Vinay Prasad, whose tenure was marked by controversial decisions. Below, we answer key questions about this transition and its implications for public health.

Who is Katherine Szarama, and what is her background?

Dr. Katherine Szarama is an experienced FDA scientist who has been named the acting director of CBER. While specific details of her career are not widely publicized, her appointment suggests a focus on regulatory continuity. She steps into a role that oversees critical products—vaccines, gene therapies, and blood safety. The Health and Human Services Department confirmed her appointment, which was first reported by Politico. Szarama's expertise likely spans biologics evaluation, as she is expected to maintain the center's operations until a permanent director is named.

What is the Center for Biologics Evaluation and Research (CBER)?

CBER is a branch of the FDA that regulates biological products, including vaccines, allergenic extracts, blood and blood components, gene therapies, and cellular and tissue-based products. Its mission is to ensure these products are safe, effective, and available. Unlike the Center for Drug Evaluation and Research (CDER), which handles traditional drugs, CBER deals with complex biologics that often involve living cells or viruses. The center also oversees the nation's blood supply to prevent contamination. CBER's decisions directly impact public health, from COVID-19 vaccines to emerging gene therapies for rare diseases.

Why did Vinay Prasad leave the FDA, and what were the controversies?

Dr. Vinay Prasad, the previous CBER director, left the FDA in late March 2025 after a turbulent tenure. His departure was expected after FDA Commissioner Marty Makary announced Prasad would return to the University of California, San Francisco. Prasad faced criticism for several controversial decisions regarding rare disease drugs and vaccines. Critics argued his approaches sometimes deviated from standard regulatory science, causing uncertainty among manufacturers and patient advocates. While Prasad defended his actions as necessary to challenge regulatory inefficiencies, his tenure highlighted tensions between innovation and regulation. The FDA has not detailed specific reasons for his exit, but it marked a significant leadership shift.

How might this change affect vaccine regulation and development?

With Szarama as acting director, vaccine regulation is expected to continue under existing frameworks. CBER has been central to COVID-19 vaccine approvals and seasonal flu shot updates. Szarama's leadership likely means maintaining rigorous safety reviews while streamlining processes for emerging vaccines (e.g., mRNA-based shots for other diseases). However, the transition could slow some policy initiatives if a permanent director is not appointed soon. The FDA will also need to address ongoing concerns about vaccine confidence and supply chain stability. Industry experts predict that Szarama will prioritize scientific rigor and transparency.

What does this mean for gene therapies and the blood supply?

Gene therapies and blood products are also under CBER's purview. Szarama's appointment comes as the FDA reviews more gene editing therapies (like CRISPR) and advanced cell therapies. Her leadership could influence expedited approvals for rare disease treatments, though the agency remains cautious. For the blood supply, CBER continues to enforce safety standards for transfusion and donation. The transition is unlikely to cause immediate disruptions, but stakeholders will watch for any shifts in regulatory tone. Patient groups hope for consistent policies that balance access with safety.

Who might be the permanent director, and when will a decision be made?

No official timeline has been announced for naming a permanent CBER director. Acting director Szarama will serve until a candidate is chosen and confirmed. Historically, permanent appointments at this level require political consideration, often influenced by the administration's priorities. Possible candidates may include other FDA veterans or academic leaders with expertise in biologics. The process could take months, especially with ongoing public health demands. In the meantime, Szarama's experience should ensure stability, but the vacancy adds uncertainty to long-term regulatory planning.

What is the overall public health impact of this leadership change?

Leadership changes at CBER are rare but consequential. The center oversees products that millions of Americans rely on—from childhood vaccines to life-saving gene therapies. Szarama's appointment signals continuity, but her ability to address pressing issues (e.g., emerging infectious diseases, new gene editing techniques) will be tested. The departure of Prasad removed a controversial figure, possibly reducing regulatory friction. For the public, the key outcomes will be maintaining vaccine safety, ensuring blood supply integrity, and accelerating access to innovative therapies. Stakeholders recommend engagement between the FDA and industry to smooth the transition.